You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Expanding the Landscape of HER2- and HER3-Targeted Therapy

Recent advancements have been made in the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers (breast cancer and gastrointestinal [GI] cancers). This has led to the development of new HER2 testing guidelines in breast cancer and new strategies are emerging for managing patients with low HER2 expression and those who are refractory to HER2-targeted therapies. HER3 overexpression has also been observed in various cancers and is currently being investigated as a therapeutic target. This curriculum discusses the new HER2 testing guidelines and explores the recent clinical advances and future prospects for HER2- and HER3-targeted therapy.

Supported by an independent educational grant from

Daiichi Sankyo

CME Activities

See All

Polling Question

Related Resources

Downloadable Slide Kit

HER2-Positive Disease in Advanced Solid Tumors

Download

Clinical Reference

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. 

HER3 signaling and targeted therapy in cancer 

Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. 

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. 

Activating HER3 mutations in breast cancer. 

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. 

Perspectives of HER2-targeting in gastric and esophageal cancer. 

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. 

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer 

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer 

Related Links

See All

Steering Committee

Nadia Harbeck, MD, PhD

Nadia Harbeck, MD, PhD

Steering Committee Chair

Professor
Breast Center
University of Munich
Munich, Germany

Fabrice André, MD, PhD

Fabrice André, MD, PhD

Professor/Chairman
Inserm Unit U981
Institut Gustave Roussy
Villejuif, France

Javier Cortes, MD, PhD

Javier Cortes, MD, PhD

Head
Breast Cancer Program
IOB Institute of Oncology
Madrid & Barcelona
Ruber International Hospital
Madrid, Spain

Giuseppe Curigliano, MD, PhD

Giuseppe Curigliano, MD, PhD

Professor, Head Division of Early Drug Development,
Istituto Europeo di Oncologia,
University of Milan
Milan, Italy

Shanu Modi, MD

Shanu Modi, MD

Associate Attending, Breast Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Kohei Shitara, MD

Kohei Shitara, MD

Chief
Department of Gastrointestinal Oncology
National Cancer Center Hospital East
Kashiwa, Japan